Cargando…
Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study
Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates insulin-like growth factor-I (IGF-I) bioactivity, and is a central player in normal growth, metabolism, and stroke recovery. However, the role of serum IGFBP-1 (s-IGFBP-1) after ischemic stroke is unclear. We determined whether s-IGFBP...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252273/ https://www.ncbi.nlm.nih.gov/pubmed/37298072 http://dx.doi.org/10.3390/ijms24119120 |
_version_ | 1785056130525822976 |
---|---|
author | Åberg, Daniel Gadd, Gustaf Jood, Katarina Redfors, Petra Stanne, Tara M. Isgaard, Jörgen Blennow, Kaj Zetterberg, Henrik Jern, Christina Åberg, N. David Svensson, Johan |
author_facet | Åberg, Daniel Gadd, Gustaf Jood, Katarina Redfors, Petra Stanne, Tara M. Isgaard, Jörgen Blennow, Kaj Zetterberg, Henrik Jern, Christina Åberg, N. David Svensson, Johan |
author_sort | Åberg, Daniel |
collection | PubMed |
description | Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates insulin-like growth factor-I (IGF-I) bioactivity, and is a central player in normal growth, metabolism, and stroke recovery. However, the role of serum IGFBP-1 (s-IGFBP-1) after ischemic stroke is unclear. We determined whether s-IGFBP-1 is predictive of poststroke outcome. The study population comprised patients (n = 470) and controls (n = 471) from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS). Functional outcome was evaluated after 3 months, 2, and 7 years using the modified Rankin Scale (mRS). Survival was followed for a minimum of 7 years or until death. S-IGFBP-1 was increased after 3 months (p < 0.01), but not in the acute phase after stroke, compared with the controls. Higher acute s-IGFBP-1 was associated with poor functional outcome (mRS score > 2) after 7 years [fully adjusted odds ratio (OR) per log increase 2.9, 95% confidence interval (CI): 1.4-5.9]. Moreover, higher s-IGFBP-1 after 3 months was associated with a risk of poor functional outcome after 2 and 7 years (fully adjusted: OR 3.4, 95% CI: 1.4–8.5 and OR 5.7, 95% CI: 2.5–12.8, respectively) and with increased mortality risk (fully adjusted: HR 2.0, 95% CI: 1.1–3.7). Thus, high acute s-IGFBP-1 was only associated with poor functional outcome after 7 years, whereas s-IGFBP-1 after 3 months was an independent predictor of poor long-term functional outcome and poststroke mortality. |
format | Online Article Text |
id | pubmed-10252273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102522732023-06-10 Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study Åberg, Daniel Gadd, Gustaf Jood, Katarina Redfors, Petra Stanne, Tara M. Isgaard, Jörgen Blennow, Kaj Zetterberg, Henrik Jern, Christina Åberg, N. David Svensson, Johan Int J Mol Sci Article Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates insulin-like growth factor-I (IGF-I) bioactivity, and is a central player in normal growth, metabolism, and stroke recovery. However, the role of serum IGFBP-1 (s-IGFBP-1) after ischemic stroke is unclear. We determined whether s-IGFBP-1 is predictive of poststroke outcome. The study population comprised patients (n = 470) and controls (n = 471) from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS). Functional outcome was evaluated after 3 months, 2, and 7 years using the modified Rankin Scale (mRS). Survival was followed for a minimum of 7 years or until death. S-IGFBP-1 was increased after 3 months (p < 0.01), but not in the acute phase after stroke, compared with the controls. Higher acute s-IGFBP-1 was associated with poor functional outcome (mRS score > 2) after 7 years [fully adjusted odds ratio (OR) per log increase 2.9, 95% confidence interval (CI): 1.4-5.9]. Moreover, higher s-IGFBP-1 after 3 months was associated with a risk of poor functional outcome after 2 and 7 years (fully adjusted: OR 3.4, 95% CI: 1.4–8.5 and OR 5.7, 95% CI: 2.5–12.8, respectively) and with increased mortality risk (fully adjusted: HR 2.0, 95% CI: 1.1–3.7). Thus, high acute s-IGFBP-1 was only associated with poor functional outcome after 7 years, whereas s-IGFBP-1 after 3 months was an independent predictor of poor long-term functional outcome and poststroke mortality. MDPI 2023-05-23 /pmc/articles/PMC10252273/ /pubmed/37298072 http://dx.doi.org/10.3390/ijms24119120 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Åberg, Daniel Gadd, Gustaf Jood, Katarina Redfors, Petra Stanne, Tara M. Isgaard, Jörgen Blennow, Kaj Zetterberg, Henrik Jern, Christina Åberg, N. David Svensson, Johan Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
title | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
title_full | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
title_fullStr | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
title_full_unstemmed | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
title_short | Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study |
title_sort | serum igfbp-1 concentration as a predictor of outcome after ischemic stroke—a prospective observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252273/ https://www.ncbi.nlm.nih.gov/pubmed/37298072 http://dx.doi.org/10.3390/ijms24119120 |
work_keys_str_mv | AT abergdaniel serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT gaddgustaf serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT joodkatarina serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT redforspetra serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT stannetaram serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT isgaardjorgen serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT blennowkaj serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT zetterberghenrik serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT jernchristina serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT abergndavid serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy AT svenssonjohan serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy |